SAS | The Power to Know
cq5dam.thumbnail.319.319
White Paper

Are You Ready for Clinical Trial Data Transparency?

What It Means for Your Business – and What’s Needed for a Successful Implementation

About this paper

Consensus is building around the idea that greater access to patient-level clinical data is a good thing – good for science, business and humanity. From a business perspective, pooling data can significantly reduce the cost of drug development while improving the efficiency of clinical trials. It can also lower clinical trial costs by reducing the number of patients needed for new studies. But data sharing and transparency raises new issues and brings a host of new questions, benefits and risks. For example, unless appro­priate safeguards are in place, open access to clinical trial data could compromise patient privacy, enable faulty science, and be a resource-intensive burden for trial sponsors and data stewards. This paper discusses different approaches to successfully implementing clinical trial data transparency while mitigating these risks.

About SAS

SAS is the leader in analytics. Through innovative software and services, SAS empowers and inspires customers around the world to transform data into intelligence. SAS gives you THE POWER TO KNOW®.

Máte SAS profil? To complete this form automatically Přihlásit se

*
*
*
*
 
*
 
 
  Yes, I would like to receive occasional emails from SAS Institute Inc. and its affiliates about SAS products and services. I understand that I can withdraw my consent at any time by clicking the opt-out link in the emails.

Veškeré osobní údaje budou zpracovány v souladu se SAS zásadami o ochraně osobních údajů.

 
 

Back to Top